AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37696264 — intervention group
Group type: EXPERIMENTAL
Intervention: delta-SIG ratio in rupture-destined aneurysms
Number of subjects: 65
Study 37696264 — intervention group
Group type: COMPARATOR
Intervention: delta-SIG ratio in unruptured intracranial aneurysms
Number of subjects: 65
Study 37696264 — intervention group
Group type: EXPERIMENTAL
Intervention: area under the receiver operating characteristic curve for delta-SIG ratio
Number of subjects: 65
Study 37696264 — intervention group
Group type: COMPARATOR
Intervention: area under the receiver operating characteristic curve for size ratio
Number of subjects: 65
Study 37696275 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacincaptad pegol 2 mg
Number of subjects: 448
Study 37696275 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 448
Study 37696281 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (50 Gy in 25 fractions of 2 Gy)
Number of subjects: 88
Study 37696281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (40.05 Gy in 15 fractions of 2.67 Gy)
Number of subjects: 88
Study 37696393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept treatment
Number of subjects: 40
Study 37696419 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective shunt
Number of subjects: 98
Study 37696419 — intervention group
Group type: COMPARATOR
Intervention: Non-shunt
Number of subjects: 98
Study 37696565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 0
Study 37696565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37696588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg every 4 weeks
Number of subjects: 702
Study 37696588 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) 40 mg every 2 weeks
Number of subjects: 702
Study 37696588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg every 4 weeks (after switch from PBO at Week 16)
Number of subjects: 702
Study 37696589 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 90 mg
Number of subjects: 549
Study 37696589 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 150 mg
Number of subjects: 549
Study 37696589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 37696589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 549
Study 37696614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 30 mg once weekly (q.w.)
Number of subjects: 0
Study 37696614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 44 mg every 2 weeks (q2w)
Number of subjects: 0
Study 37696614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37696621 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFAs)
Number of subjects: 736
Study 37696621 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA
Number of subjects: 736
Study 37696621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 736
Study 37696629 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg melatonin administered rectally via an enema daily for 28 days
Number of subjects: 21
Study 37696629 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered rectally via an enema daily for 28 days
Number of subjects: 21
Study 37696633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music listening
Number of subjects: 70
Study 37696633 — intervention group
Group type: COMPARATOR
Intervention: Active audiobooks listening
Number of subjects: 70
Study 37696652 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 612
Study 37696652 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 612
Study 37696652 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (excluding pseudo-progression)
Number of subjects: 612
Study 37696667 — intervention group
Group type: EXPERIMENTAL
Intervention: Upacicalcet
Number of subjects: 153
Study 37696667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 37696935 — intervention group
Group type: EXPERIMENTAL
Intervention: lefitolimod (TLR9 agonist)/placebo
Number of subjects: 43
Study 37696935 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs)
Number of subjects: 43
Study 37696935 — intervention group
Group type: COMPARATOR
Intervention: placebo/placebo
Number of subjects: 43
Study 37696935 — intervention group
Group type: EXPERIMENTAL
Intervention: lefitolimod/bNAb
Number of subjects: 43
Study 37696968 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted CPR (V-CPR)
Number of subjects: 147
Study 37696968 — intervention group
Group type: COMPARATOR
Intervention: Telephone-assisted CPR (T-CPR)
Number of subjects: 147
Study 37696968 — intervention group
Group type: COMPARATOR
Intervention: Unassisted CPR (U-CPR)
Number of subjects: 147
Study 37697121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 0
Study 37697124 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG features
Number of subjects: 123
Study 37697124 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI features
Number of subjects: 123
Study 37697124 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent clinical predictors
Number of subjects: 123
Study 37697129 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention (6-week program with online lectures, instructional videos, educational handouts, and bedside teaching)
Number of subjects: 430
Study 37697129 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention
Number of subjects: 430
Study 37697134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (PDE-5 inhibitor)
Number of subjects: 160
Study 37697238 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using radiomic features from multiparametric MRI for predicting molecular subgroups of PLGGs.
Number of subjects: 61
Study 37697238 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using radiomic features from multiparametric MRI for predicting KIAA1549-BRAF fusion.
Number of subjects: 61
Study 37697327 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes (closed pod system, 3% nicotine salt, tobacco flavour) plus cytisine
Number of subjects: 800
Study 37697327 — intervention group
Group type: COMPARATOR
Intervention: e-cigarettes alone
Number of subjects: 800
Study 37697327 — intervention group
Group type: COMPARATOR
Intervention: cytisine alone
Number of subjects: 800
Study 37697331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifactor model of the IKDC
Number of subjects: 606
Study 37697331 — intervention group
Group type: EXPERIMENTAL
Intervention: One-factor model of the IKDC
Number of subjects: 606
Study 37697331 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-factor model of the IKDC
Number of subjects: 606
Study 37697331 — intervention group
Group type: EXPERIMENTAL
Intervention: IKDC questionnaire
Number of subjects: 606
Study 37697331 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary factors (symptoms, activity level, activities of daily living, sport)
Number of subjects: 606
Study 37697386 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-span rigid fixed prostheses
Number of subjects: 9
Study 37697386 — intervention group
Group type: EXPERIMENTAL
Intervention: Splitting the full arch prosthesis
Number of subjects: 9
Study 37697389 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression sleeve
Number of subjects: 15
Study 37697389 — intervention group
Group type: COMPARATOR
Intervention: No compression sleeve
Number of subjects: 15
Study 37697396 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 52
Study 37697402 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound diagnosis of TOS
Number of subjects: 82
Study 37697429 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of traditional care with modern TB care, including referral linkage, training of health professionals and traditional care providers, and TB screening at traditional health care sites.
Number of subjects: 0
Study 37697429 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 37697491 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire
Number of subjects: 408
Study 37697491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rinse activated matrix metalloproteinase-8 (aMMP-8) point-of-care test (POCT)
Number of subjects: 408
Study 37697491 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of gingival bleeding on brushing (GBoB)
Number of subjects: 408
Study 37697491 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning classifiers (Random Forest analyses)
Number of subjects: 408
Study 37697655 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 713
Study 37697655 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical diabetes (subclinical DM)
Number of subjects: 713
Study 37697655 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 713
Study 37697666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodilatation with hyaluronic acid (20 mL in total) + physical therapy
Number of subjects: 0
Study 37697666 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 0
Study 37697666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodilatation with hyaluronic acid + physical therapy
Number of subjects: 0
Study 37697745 — intervention group
Group type: EXPERIMENTAL
Intervention: 10min texting (Group A)
Number of subjects: 50
Study 37697745 — intervention group
Group type: EXPERIMENTAL
Intervention: 15min texting (Group B)
Number of subjects: 50
Study 37697745 — intervention group
Group type: EXPERIMENTAL
Intervention: 10min writing (Group C)
Number of subjects: 50
Study 37697745 — intervention group
Group type: EXPERIMENTAL
Intervention: 15min writing (Group D)
Number of subjects: 50
Study 37697745 — intervention group
Group type: COMPARATOR
Intervention: Control group (15min talking or watching, Group E)
Number of subjects: 50
Study 37697811 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BNX)
Number of subjects: 268
Study 37697811 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy (MMT)
Number of subjects: 268
Study 37697813 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bridging strategy used during edoxaban interruption (178 procedures)
Number of subjects: 2089
Study 37697813 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban interruption
Number of subjects: 2089
Study 37698366 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA
Number of subjects: 12466
Study 37698366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12466
Study 37698430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 20
Study 37698430 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 20
Study 37698443 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention for COPD (details not available)
Number of subjects: 0
Study 37698443 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not available)
Number of subjects: 0
Study 37698477 — intervention group
Group type: COMPARATOR
Intervention: Coronary CTA-derived FFR normal results
Number of subjects: 900
Study 37698477 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA-derived FFR abnormal results
Number of subjects: 900
Study 37698478 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Erythropoietin
Number of subjects: 0
Study 37698478 — intervention group
Group type: COMPARATOR
Intervention: Qualitative brain injury scoring by radiologists
Number of subjects: 0
Study 37698480 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D CT scans
Number of subjects: 150
Study 37698480 — intervention group
Group type: COMPARATOR
Intervention: Follow-up of inconclusive group participants
Number of subjects: 150
Study 37698591 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention in a support group setting via Zoom
Number of subjects: 0
Study 37698604 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine massage after vaginal delivery before placental delivery (n: 128)
Number of subjects: 242
Study 37698604 — intervention group
Group type: COMPARATOR
Intervention: No uterine massage (Control group, n: 114)
Number of subjects: 242
Study 37698632 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Durvalumab combined with Gemcitabine and Cisplatin or Carboplatin
Number of subjects: 0
Study 37698645 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic segmentation-based dosimetry
Number of subjects: 209
Study 37698645 — intervention group
Group type: COMPARATOR
Intervention: Count threshold-based dosimetry
Number of subjects: 209
Study 37698662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of triamcinolone acetonide (TA) (40 mg) and VISCOAT (sodium chondroitin sulfate 20 mg and sodium hyaluronate 15 mg)
Number of subjects: 75
Study 37698662 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) (40 mg) in the posterior subtenon space
Number of subjects: 75
Study 37698662 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal triamcinolone (4 mg/100µl)
Number of subjects: 75
Study 37698662 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 37698660 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Monthly Regimen (mMR), total dose-5.5 g, with intake of oral GCs after completion of intravenous infusions.
Number of subjects: 62
Study 37698660 — intervention group
Group type: COMPARATOR
Intervention: Weekly Regimen (WR), total dose-4.5 g.
Number of subjects: 62
Study 37698660 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Monthly Regimen (mMR)
Number of subjects: 62
Study 37698660 — intervention group
Group type: COMPARATOR
Intervention: Weekly Regimen (WR)
Number of subjects: 62
Study 37698745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health exercise intervention (daily steps and resistance training data entered into an app)
Number of subjects: 7
Study 37698745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health exercise intervention
Number of subjects: 7
Study 37698774 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 + SIIV
Number of subjects: 1128
Study 37698774 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 1128
Study 37698774 — intervention group
Group type: COMPARATOR
Intervention: SIIV
Number of subjects: 1128
Study 37698836 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-mg galcanezumab
Number of subjects: 459
Study 37698836 — intervention group
Group type: EXPERIMENTAL
Intervention: 240-mg galcanezumab
Number of subjects: 459
Study 37698836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 37698862 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention for a mean of 120 days after hospital discharge
Number of subjects: 782
Study 37698862 — intervention group
Group type: COMPARATOR
Intervention: Usual postdischarge care (Control)
Number of subjects: 782
Study 37698881 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib (50 mg once daily in 28-day cycles)
Number of subjects: 35
Study 37698896 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Care Family Navigator (FCFN) intervention
Number of subjects: 80
Study 37698896 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (clinical case management services)
Number of subjects: 80
Study 37698915 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Nights, Better Days (BNBD-NDD) eHealth behavioral intervention delivered to parents (5 sessions)
Number of subjects: 0
Study 37698915 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 37698922 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxLDL
Number of subjects: 306
Study 37698922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxHDL
Number of subjects: 306
Study 37698922 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma oxHDL levels
Number of subjects: 306
Study 37698922 — intervention group
Group type: EXPERIMENTAL
Intervention: oxHDL
Number of subjects: 306
Study 37698922 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Met136 mono-oxidation and Trp132 dioxidation of HDL
Number of subjects: 306
Study 37698922 — intervention group
Group type: EXPERIMENTAL
Intervention: Met136 mono-oxidation
Number of subjects: 306
Study 37699050 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with 5% free-base nicotine
Number of subjects: 132
Study 37699050 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with 25% free-base nicotine
Number of subjects: 132
Study 37699050 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with 45% free-base nicotine
Number of subjects: 132
Study 37699050 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with 65% free-base nicotine
Number of subjects: 132
Study 37699050 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with 85% free-base nicotine
Number of subjects: 132
Study 37699050 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with 20 mg/mL total nicotine concentration
Number of subjects: 132
Study 37699050 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with 50 mg/mL total nicotine concentration
Number of subjects: 132
Study 37699064 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 μg RSVPreF3-AS01E (third dose)
Number of subjects: 122
Study 37699064 — intervention group
Group type: COMPARATOR
Intervention: Previous 2 doses of RSVPreF3-AS01E
Number of subjects: 122
Study 37699161 — intervention group
Group type: EXPERIMENTAL
Intervention: START (Startle Adjuvant Rehabilitation Therapy) with 105-dB white noise GO cues during one third of trials
Number of subjects: 42
Study 37699161 — intervention group
Group type: EXPERIMENTAL
Intervention: START (Startle Adjuvant Rehabilitation Therapy)
Number of subjects: 42
Study 37699161 — intervention group
Group type: COMPARATOR
Intervention: Control group (77-dB GET READY and GO cues only)
Number of subjects: 42
Study 37699161 — intervention group
Group type: COMPARATOR
Intervention: Control group (mild controls)
Number of subjects: 42
Study 37699162 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib (PIK3CA inhibitor)
Number of subjects: 203
Study 37699162 — intervention group
Group type: EXPERIMENTAL
Intervention: Poziotinib (EGFR/HER2 inhibitor)
Number of subjects: 203
Study 37699162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (FGFR inhibitor)
Number of subjects: 203
Study 37699162 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (CDK4/6 inhibitor)
Number of subjects: 203
Study 37699162 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab ± Tremelimumab (anti-PD-L1/CTLA-4 inhibitor)
Number of subjects: 203
Study 37699162 — intervention group
Group type: COMPARATOR
Intervention: Crossover to arm 5 (Durvalumab ± Tremelimumab) after progressive disease in arms 1-4
Number of subjects: 203
Study 37699237 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing chemotherapy symptoms (e.g., medication, home remedies)
Number of subjects: 0
Study 37699237 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipating and mitigating symptoms (e.g., management of symptoms at home, anticipatory guidance)
Number of subjects: 0
Study 37699237 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowing when to seek care (e.g., unexpected and unusual symptoms)
Number of subjects: 0
Study 37699333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab beyond confirmed progressive disease (PD) per RECIST v1.1
Number of subjects: 799
Study 37699601 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-sparing volumetric-modulated arc therapy (SSV)
Number of subjects: 19
Study 37699601 — intervention group
Group type: COMPARATOR
Intervention: Non-SSV
Number of subjects: 19
Study 37699623 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of a Reveal Linq device (Medtronic) and percutaneous PFO closure performed 2 months after device implantation.
Number of subjects: 250
Study 37699623 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence and burden of AF in the 2 months prior to PFO closure and up to 2 years after PFO closure.
Number of subjects: 250
Study 37699630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Q-Griffithsin (Q-GRFT)
Number of subjects: 40
Study 37699630 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial version of SPRAY PAL questionnaire
Number of subjects: 40
Study 37699630 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised version of SPRAY PAL questionnaire
Number of subjects: 40
Study 37699634 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment (Tislelizumab) starting at Day 8 of radiation (concurrent plan)
Number of subjects: 0
Study 37699634 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment (Tislelizumab) starting 2 weeks after completion of radiation (sequential plan)
Number of subjects: 0
Study 37699634 — intervention group
Group type: COMPARATOR
Intervention: Long-course radiotherapy plus concurrent capecitabine (control arm)
Number of subjects: 0
Study 37699634 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (all arms)
Number of subjects: 0
Study 37699636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydration
Number of subjects: 254
Study 37699636 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 254
Study 37699654 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 90 mg
Number of subjects: 3162
Study 37699654 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 150 mg
Number of subjects: 3162
Study 37699654 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab
Number of subjects: 3162
Study 37699654 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib
Number of subjects: 3162
Study 37699654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3162
Study 37699709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous KPL-404 dose 0.03, 0.3, 1, 3, or 10 mg/kg
Number of subjects: 0